Glenmark Shares Drop To Six-Year Low As U.S. FDA Approval For Nasal Spray Delayed
The U.S. FDA has issued a complete response letter regarding Glenmark’s nasal spray Ryaltris. (Photographer: Martin Leissl/Bloomberg)

Glenmark Shares Drop To Six-Year Low As U.S. FDA Approval For Nasal Spray Delayed

Shares of Glenmark Pharmaceuticals Ltd. fell to their lowest in six years on Monday after the company said the U.S. Food and Drug Administration didn’t approve its key nasal spray—a move that will ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.